Call us: + 31 (0)20 - 4350 580

Home > News > Articles & whitepapers

Articles & whitepapers

SMS-oncology stands out from the crowd - SAS Visual Analytics

SMS-oncology stands out from the crowd - SAS Visual Analytics
4 July 2018

Customer story from OCS Consulting: Powerful analytics from SAS Visual enable SMS-oncology to rapidly identify trends in clinical trials as they unfold.

Read more

Comparison of Phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies

Comparison of Phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies
10 May 2016

Antigen-specific immunotherapy targets particular tumour associated antigens in order to address and eradicate solely tumour-marker defined cancer cells. In contrast, non-specific agents generally stimulate the immune system by...

Read more

Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer...

Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents
2 March 2015

Cytotoxic anticancer agents are designed to kill tumor cells by interfering with cell division mechanisms. In contrast, non-cytotoxic anticancer agents intend to inhibit cancer growth by targeting specific proteins or signaling...

Read more

Put to the Test

Put to the Test
5 January 2015

Typical Phase 1 oncology studies have changed and evolved as new techniques have developed, and target therapies have begun to reach the market. By looking at the types of drugs used, the dose levels tested and the patient popu...

Read more

Personalised Medicine in Cancer Treatment: Hype or Hope?

Personalised Medicine in Cancer Treatment: Hype or Hope?
1 January 2012

Edwin Klumper of SMS-oncology discusses the developments that have taken place in personalised medicine, reviewing the impact they have had on the industry and the challenges that lie ahead.

Read more